611 related articles for article (PubMed ID: 26933175)
1. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
[TBL] [Abstract][Full Text] [Related]
2. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
4. Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer.
Ito F; Ku AW; Bucsek MJ; Muhitch JB; Vardam-Kaur T; Kim M; Fisher DT; Camoriano M; Khoury T; Skitzki JJ; Gollnick SO; Evans SS
PLoS One; 2015; 10(11):e0143370. PubMed ID: 26599402
[TBL] [Abstract][Full Text] [Related]
5. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
6. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
[TBL] [Abstract][Full Text] [Related]
7. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer.
Löffler MW; Nussbaum B; Jäger G; Jurmeister PS; Budczies J; Pereira PL; Clasen S; Kowalewski DJ; Mühlenbruch L; Königsrainer I; Beckert S; Ladurner R; Wagner S; Bullinger F; Gross TH; Schroeder C; Sipos B; Königsrainer A; Stevanović S; Denkert C; Rammensee HG; Gouttefangeas C; Haen SP
Front Immunol; 2019; 10():2526. PubMed ID: 31803175
[No Abstract] [Full Text] [Related]
8. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
9. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
10. Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway.
Zhang SA; Niyazi HE; Hong W; Tuluwengjiang GL; Zhang L; Zhang Y; Su WP; Bao YX
Tumour Biol; 2017 Mar; 39(3):1010428317692237. PubMed ID: 28351328
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
Peng J; Hamanishi J; Matsumura N; Abiko K; Murat K; Baba T; Yamaguchi K; Horikawa N; Hosoe Y; Murphy SK; Konishi I; Mandai M
Cancer Res; 2015 Dec; 75(23):5034-45. PubMed ID: 26573793
[TBL] [Abstract][Full Text] [Related]
12. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy.
Shi L; Wang J; Ding N; Zhang Y; Zhu Y; Dong S; Wang X; Peng C; Zhou C; Zhou L; Li X; Shi H; Wu W; Long X; Wu C; Liao W
Nat Commun; 2019 Nov; 10(1):5421. PubMed ID: 31780645
[TBL] [Abstract][Full Text] [Related]
13. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
[TBL] [Abstract][Full Text] [Related]
14. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
[TBL] [Abstract][Full Text] [Related]
15. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
[No Abstract] [Full Text] [Related]
16. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
17. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J
Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
19. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
